Speaker Profile
Biography
Dr. Daneshjou studied Bioengineering at Rice University before matriculating to Stanford School of Medicine where she completed her MD and a PhD in Genetics with Dr. Russ Altman as part of the medical scientist training program. She completed dermatology residency at Stanford as part of the research track and completed a postdoc in Biomedical Data Science with Dr. James Zou. She currently is the assistant director of the Center of Excellence for Precision Heath Pharmacogenomics, director of informatics for the Stanford Skin Innovation and Interventional Research Group (SIIRG), a founding member of the Translational AI in Dermatology (TRAIND) group, and a faculty affiliate of Human-centered Artificial Intelligence (HAI) and the AI in Medicine and Imaging (AIMI) centers.
Session Abstract – PMWC 2026 Silicon Valley
Track Co-Chairs:
- William Oh, Yale Cancer Center
- David Reese, Amgen
Patient-centric data, such as Real-World Evidence (RWE) and Real-World Data (RWD), has become critical in reshaping drug development and healthcare decision-making. Over the last few years, regulatory agencies like the FDA and EMA have increasingly embraced RWE/RWD for decision-making processes, influencing everything from new drug indications to post-marketing surveillance. The integration of RWE and RWD is not only supporting clinical trial design and regulatory approvals, but also enabling precision medicine by providing deeper insights into patient subpopulations and their outcomes
Sessions:
- TBA